Galantamine versus donepezil in Chinese patients with Alzheimer&rsquo;s disease: results from a randomized, double-blind study

Galantamine versus donepezil in Chinese patients with Alzheimer&rsquo;s disease: results from a randomized, double-blind study

Zhenxin Zhang,1 Lu Yu,2 Maren Gaudig,3 Barbara Sch&auml;uble,4 Ute Richarz51Department of Neurology of Peking Union Medical College Hospital, 2Xi&rsquo;an Janssen Pharmaceutical Ltd, Beijing, China; 3Health Economics and Reimbursement, Janssen-Cilag EMEA, Neuss, Germany; 4Formerly of...

Full description

Bibliographic Details
Main Authors:	Zhang Z, Yu L, Gaudig M, Sch&auml;uble B, Richarz U
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-12-01
Series:	Neuropsychiatric Disease and Treatment
Online Access:	http://www.dovepress.com/galantamine-versus-donepezil-in-chinese-patients-with-alzheimerrsquos--a11671

Similar Items

Galantamine vs donepezil in the treatment of Alzheimer's disease.
by: Goldlist, B, et al.
Published: (2003)

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer&rsquo;s disease receiving donepezil
by: Kano O, et al.
Published: (2013-02-01)

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
by: Richard A Hansen, et al.
Published: (2008-06-01)

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
by: Wilcock, G, et al.
Published: (2003)

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
by: E Loveman, et al.
Published: (2006-01-01)

QT interval prolongation and with donepezil, rivastigmine and galantamine
by: Katie Malone, et al.
Published: (2020-08-01)

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review
by: J. Bryant, et al.
Published: (2001-01-01)

Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients
by: Zhang N, et al.
Published: (2018-10-01)

A long-term comparison of galantamine and donepezil in the treatment of moderate-to-severe Alzheimer's disease: An intent-to-treat analysis
by: Wilcock, G, et al.
Published: (2003)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
by: Dan-Dan Li, et al.
Published: (2019-05-01)

Effects of Galantamine and Donepezil on Active and Passive Avoidance Tests in Rats With Induced Hypoxia
by: Dimitrova Darinka Slavcheva, et al.
Published: (2006-01-01)

The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease
by: Shoichi Sasaki, et al.
Published: (2014-05-01)

Galantamine in Alzheimer's disease.
by: Razay, G, et al.
Published: (2008)

Recent achievements in the management of Raynaud&rsquo;s phenomenon
by: Magnus Baumh&auml;kel, et al.
Published: (2010-03-01)

The Effects of Donepezil, Galantamine, Rivastigmine and Memantine on Mini-Mental State Examination and Mean Flow Velocity in Patients with Vascular Dementia: A Double-Blinded Randomized Clinical Trial
by: Farhad Iranmanesh, et al.
Published: (2020-03-01)

Ceruloplasmin and iron in Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease: a synopsis of recent studies
by: Kristinsson J, et al.
Published: (2012-11-01)

Galantamine treatment in Alzheimer&#39;s disease: response and long-term outcome in a routine clinical setting
by: Wallin &Aring;K, et al.
Published: (2011-09-01)

An update on the toxicity of A&beta; in Alzheimer&rsquo;s disease
by: J&uuml;rgen G&ouml;tz, et al.
Published: (2008-12-01)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
by: Hager K, et al.
Published: (2014-10-01)

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease
by: Woo FY, et al.
Published: (2015-06-01)

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model
by: M Bond, et al.
Published: (2012-04-01)

Use of Methylphenidate in Excessive Daytime Sleepiness in Alzheimer’s Patients Treated with Donepezil: Case Series
by: Bidzan L, et al.
Published: (2020-11-01)

Long-term effect of galantamine on cognitive function in patients with Alzheimer’s disease versus a simulated disease trajectory: an observational study in the clinical setting
by: Nakagawa R, et al.
Published: (2017-04-01)

Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report
by: Yu Mimura, et al.
Published: (2020-05-01)

Effects of 3R, 16S-2-hydroxyethyl apovincaminate (HEAPO), donepezil and galantamine on learning and memory retention in naïve Wistar rats
by: Dimitrova Darinka, et al.
Published: (2023-03-01)

The beneficial effects of galantamine on caregiver time in Alzheimer's disease
by: Sano, M, et al.
Published: (2003)

The effects of galantamine treatment on caregiver time in Alzheimer's disease.
by: Sano, M, et al.
Published: (2003)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
by: Yi-Ting Lin, et al.
Published: (2019-05-01)

Donepezil-Loaded Nanocarriers for the Treatment of Alzheimer’s Disease: Superior Efficacy of Extracellular Vesicles Over Polymeric Nanoparticles
by: Oliveira Silva R, et al.
Published: (2024-02-01)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
by: Deardorff WJ, et al.
Published: (2016-10-01)

Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer&rsquo;s disease
by: Fiona E McAlpine, et al.
Published: (2008-11-01)

Donepezil for the treatment of agitation in Alzheimer's disease.
by: Howard, R, et al.
Published: (2007)

Donepezil for dementia due to Alzheimer's disease
by: Birks, J, et al.
Published: (2018)

Combined Donepezil with Astaxanthin via Nanostructured Lipid Carriers Effective Delivery to Brain for Alzheimer’s Disease in Rat Model
by: Shehata MK, et al.
Published: (2023-07-01)

Can we predict the response to Galantamine in Alzheimer`s disease patients?
by: Carmen Gavan, et al.
Published: (2015-09-01)

Parenting adolescents with cystic fibrosis: the adolescents&rsquo; and young adults&rsquo; perspectives
by: Bregnballe V, et al.
Published: (2011-11-01)

Update on the use of memantine in Alzheimer&rsquo;s disease
by: Robert J van Marum
Published: (2009-03-01)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
by: Wilcock, G, et al.
Published: (2000)

Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer’s disease
by: Nakamura K, et al.
Published: (2014-09-01)

Effect of Psychoeducational Intervention on Donepezil Retention Rate and Analysis of Reasons for the Discontinuation in Patients with Alzheimer’s Dementia: A Randomized Study
by: Kamei T, et al.
Published: (2021-09-01)